The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I Receptors ALK4, ALK5, and ALK7
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Singer, A. J., & Clark, R. A. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411006 · Cited by 6,106
TGF-β signalling from cell membrane to nucleus through SMAD proteins
Heldin, C.-H., Miyazono, K., & ten Dijke, P. (1997) · Nature · doi:10.1038/37284 · Cited by 3,696
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Dennler, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3091 · Cited by 1,793
Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., & Hill, C. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.65 · Cited by 1,634
Self-citationBalancing the activation state of the endothelium via two distinct TGF-beta type I receptors
Goumans, M.-J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1743 · Cited by 1,123
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4
Nakao, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5353 · Cited by 1,070
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. J., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C., et al. (1999) · Nature Cell Biology · doi:10.1038/12971 · Cited by 911
Self-citation
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation
Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T. R., Peng, X., Hu, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1979 · Cited by 1,165
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Mediators of Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.2 · Cited by 710
Smad3 as a mediator of the fibrotic response
Flanders, K. C. (2004) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2004.00377.x · Cited by 608
TGF-β Tumor Suppression through a Lethal EMT
David, C. J., Huang, Y.-H., Chen, M., Su, J., Zou, Y., Bardeesy, N., Iacobuzio-Donahue, C. A., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.01.009 · Cited by 593
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Transforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 517
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1
Su, J., Morgani, S. M., David, C. J., Wang, Q., Er, E. E., Huang, Y.-H., Basnet, H., Zou, Y., Shu, W., Soni, R. K., et al. (2020) · Nature · doi:10.1038/s41586-019-1897-5 · Cited by 492
Spencer, M., Yao-Borengasser, A., Unal, R., Rasouli, N., Gurley, C. M., Zhu, B., Peterson, C. A., & Kern, P. A. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2010 · Cited by 439
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
Immunomodulation‐Enhanced Nanozyme‐Based Tumor Catalytic Therapy
Xu, B., Cui, Y., Wang, W., Li, S., Lyu, C., Wang, S., Bao, W., Wang, H., Qin, M., Liu, Z., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003563 · Cited by 404
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 391
Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology
Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J. V., Lin, A. H., Crews, L., Tremblay, P., Mathews, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27341 · Cited by 355
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Peng, J., Li, Q., Wigglesworth, K., Rangarajan, A., Kattamuri, C., Peterson, R. T., Eppig, J. J., Thompson, T. B., & Matzuk, M. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218020110 · Cited by 321
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 261
Wesolowska, A., Kwiatkowska, A., Slomnicki, L., Dembinski, M., Master, A., Sliwa, M., Franciszkiewicz, K., Chouaib, S., & Kaminska, B. (2008) · Oncogene · doi:10.1038/sj.onc.1210683 · Cited by 258
The specificities of small molecule inhibitors of the TGFß and BMP pathways
Vogt, J., Traynor, R., & Sapkota, G. P. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.06.019 · Cited by 256
Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles
Bellina, F., Cauteruccio, S., & Rossi, R. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.02.075 · Cited by 254
Skeletal Muscle Wasting and Renewal: A Pivotal Role of Myokine IL-6
Belizário, J. E., Fontes-Oliveira, C. C., Borges, J. P., Kashiabara, J. A., & Vannier, E. (2016) · SpringerPlus · doi:10.1186/s40064-016-2197-2 · Cited by 244
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
Ramachandran, A., Vizán, P., Das, D., Chakravarty, P., Vogt, J., Rogers, K. W., Müller, P., Hinck, A. P., Sapkota, G. P., & Hill, C. S. (2018) · eLife · doi:10.7554/elife.31756 · Cited by 204
Pechkovsky, D. V., Prêle, C. M., Wong, J., Hogaboam, C. M., McAnulty, R. J., Laurent, G. J., Zhang, S. S.-M., Selman, M., Mutsaers, S. E., & Knight, D. A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.12.022 · Cited by 127
TGFβ-Smad2 Signaling Regulates the Cdh1-APC/SnoN Pathway of Axonal Morphogenesis
Stegmüller, J., Huynh, M. A., Yuan, Z., Konishi, Y., & Bonni, A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3061-07.2008 · Cited by 86
“We also characterized the biochemical and biological response of neurons to small molecule inhibitors of TGF receptors, SB431542 and SB505124 (Inman et al., 2002; DaCosta Byfield et al., 2004).”
BackgroundDubon, M. J., Yu, J., Choi, S., & Park, K. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25863 · Cited by 76
Metadata
- Authors
- DaCosta Byfield, S., Major, C., Laping, N. J., & Roberts, A. B.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 65
- Issue
- 3
- Pages
- 744-752
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W1905104097
- Cited by
- 414
- References
- 33
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.